米卡芬净对西班牙常见和新出现的酵母及霉菌临床分离株的体外活性研究。
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
作者信息
Cuenca-Estrella Manuel, Gomez-Lopez Alicia, Mellado Emilia, Monzon Araceli, Buitrago Maria J, Rodriguez-Tudela Juan L
机构信息
Mycology Department, Spanish National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2009 May;53(5):2192-5. doi: 10.1128/AAC.01543-08. Epub 2009 Feb 17.
Abstract
A collection of 2,278 isolates belonging to 86 different fungal species was tested with micafungin and eight other drugs using the EUCAST procedures. Micafungin was active against species of Candida and Aspergillus (even azole-resistant species) as well as Penicillium spp., Scedosporium apiospermum, and Acremonium spp. It was inactive for species of Basidiomycota and Mucorales and for multiresistant species such as those of Fusarium.
摘要
采用欧洲抗菌药物敏感性试验委员会（EUCAST）的方法，用米卡芬净和其他八种药物对2278株分属于86种不同真菌的菌株进行了测试。米卡芬净对念珠菌属和曲霉属（包括对唑类耐药的菌种）以及青霉属、尖端赛多孢和枝顶孢属的菌种有活性。对担子菌门和毛霉目的菌种以及对多种药物耐药的菌种如镰刀菌属的菌种无活性。
相似文献
1
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
Antimicrob Agents Chemother. 2009 May;53(5):2192-5. doi: 10.1128/AAC.01543-08. Epub 2009 Feb 17.
2
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Diagn Microbiol Infect Dis. 2015 Aug;82(4):303-13. doi: 10.1016/j.diagmicrobio.2015.04.008. Epub 2015 Apr 29.
3
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Antimicrob Agents Chemother. 2006 Mar;50(3):917-21. doi: 10.1128/AAC.50.3.917-921.2006.
4
Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
Med Mycol. 2009 Mar;47(2):145-8. doi: 10.1080/13693780802262123. Epub 2008 Jul 30.
5
Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
J Clin Microbiol. 2006 Dec;44(12):4342-4. doi: 10.1128/JCM.01550-06. Epub 2006 Oct 4.
6
In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
Antimicrob Agents Chemother. 2011 Oct;55(10):4652-8. doi: 10.1128/AAC.00291-11. Epub 2011 Aug 8.
7
[In vitro antifungal activity of micafungin].
Rev Iberoam Micol. 2009 Mar 31;26(1):35-41. doi: 10.1016/S1130-1406(09)70006-3. Epub 2009 May 7.
8
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
Antimicrob Agents Chemother. 2008 Apr;52(4):1396-400. doi: 10.1128/AAC.01512-07. Epub 2008 Jan 22.
9
Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
Antimicrob Agents Chemother. 2005 Dec;49(12):5157-9. doi: 10.1128/AAC.49.12.5157-5159.2005.
10
Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
J Clin Microbiol. 2013 Aug;51(8):2571-81. doi: 10.1128/JCM.00308-13. Epub 2013 May 29.
引用本文的文献
1
Overview on the Infections Related to Rare Species.
Pathogens. 2022 Aug 24;11(9):963. doi: 10.3390/pathogens11090963.
2
Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.
Antimicrob Agents Chemother. 2022 May 17;66(5):e0172521. doi: 10.1128/aac.01725-21. Epub 2022 Apr 12.
3
Low sensitivity of conventional fungal agars in fungemia by Rhodotorula mucilaginosa: description of two cases.
Ann Clin Microbiol Antimicrob. 2021 Mar 27;20(1):21. doi: 10.1186/s12941-021-00427-w.
4
Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC).
Rev Esp Quimioter. 2020 Apr;33(2):110-115. doi: 10.37201/req/094.2019. Epub 2020 Feb 14.
5
Fatal breakthrough mucormycosis in a multivisceral transplant patient receiving micafungin: Case report and literature review.
IDCases. 2018 Mar 24;12:76-79. doi: 10.1016/j.idcr.2018.03.017. eCollection 2018.
6
Candidemia in patients with prolonged fever in Kashan, Iran.
Curr Med Mycol. 2016 Sep;2(3):20-26. doi: 10.18869/acadpub.cmm.2.3.20.
7
Epidemiology and Microbiologic Characterization of Nosocomial Candidemia from a Brazilian National Surveillance Program.
PLoS One. 2016 Jan 25;11(1):e0146909. doi: 10.1371/journal.pone.0146909. eCollection 2016.
8
Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.
Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):367-83. doi: 10.1007/s10096-014-2240-6. Epub 2014 Sep 16.
9
Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011.
BMC Infect Dis. 2013 Jul 30;13:353. doi: 10.1186/1471-2334-13-353.
10
A case of Schizophyllum commune sinusitis following unrelated cord blood transplantation for acute lymphoblastic leukemia.
Int J Hematol. 2013 Aug;98(2):261-3. doi: 10.1007/s12185-013-1362-4. Epub 2013 May 18.
本文引用的文献
1
EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.
Clin Microbiol Infect. 2008 Oct;14(10):982-4. doi: 10.1111/j.1469-0691.2008.02086.x.
2
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Diagn Microbiol Infect Dis. 2008 Oct;62(2):182-5. doi: 10.1016/j.diagmicrobio.2008.05.007. Epub 2008 Jul 1.
3
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.
4
Micafungin activity against Candida albicans with diverse azole resistance phenotypes.
J Antimicrob Chemother. 2008 Aug;62(2):349-55. doi: 10.1093/jac/dkn156. Epub 2008 Apr 23.
5
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
J Clin Microbiol. 2008 Mar;46(3):842-9. doi: 10.1128/JCM.02122-07. Epub 2008 Jan 16.
6
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.
Clin Microbiol Infect. 2008 Apr;14(4):398-405. doi: 10.1111/j.1469-0691.2007.01935.x. Epub 2008 Jan 11.
7
Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006.
Antimicrob Agents Chemother. 2008 Feb;52(2):778-81. doi: 10.1128/AAC.01140-07. Epub 2007 Dec 10.
8
EUCAST technical note on fluconazole.
Clin Microbiol Infect. 2008 Feb;14(2):193-5. doi: 10.1111/j.1469-0691.2007.01899.x. Epub 2007 Dec 5.
9
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
J Clin Microbiol. 2008 Jan;46(1):150-6. doi: 10.1128/JCM.01901-07. Epub 2007 Nov 21.
10
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antimicrob Agents Chemother. 2008 Jan;52(1):321-8. doi: 10.1128/AAC.00699-07. Epub 2007 Oct 15.
Zotero 插件